Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Rendell, Jennifer M ^a   Shuttleworth, Claire ^a   Jochim, Janina ^a   Diamond, Peter R ^b   Brett, Daniel ^a   Amit, Ben H ^c   Hawton, Keith ^c   Mcshane, Rupert ^c   Cipriani, Andrea ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATOMOXETINE; CYCLOSERINE; DEXTROMETHORPHAN; GLUTAMATE RECEPTOR AGONIST; KETAMINE; LANICEMINE; MEMANTINE; QUINIDINE; QUINOLINIC ACID; RAPASTINEL; RISLENEMDAZ; TRAMADOL;

ADVERSE OUTCOME; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; COMORBIDITY; CONSTIPATION; DELUSION; DEPRESSION; DIARRHEA; DISSOCIATIVE DISORDER; DIZZINESS; DROWSINESS; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; HYPOMANIA; HYPOTENSION; INSOMNIA; MANIA; NAUSEA; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESSNESS; SEIZURE; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URINARY TRACT DISEASE; VOMITING; XEROSTOMIA;

EID: 85041704074     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011611     Document Type: Article

References (67)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here?. Biological Psychiatry 2012;72(7):537-47.
2. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003;14(3):387-91.
3. Abrams R, Morrison JE, Villasenor A, Hencmann D, Da Fonseca M, Mueller W. Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Prog 1993;40(3):63-6.
4. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 2013;230(2):291-8.
5. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Europen Neuropsychopharmacology 1995;5 Suppl:71-5.
6. Altman DG, Bland JM. Detecting skewness from summary information. British Medical Journal 1996;313(7066):1200.
7. Amit B, Caddy C, McCloud T, Rendell J, Hawton K, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews 2015, Issue (submitted).
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington D.C.: American Psychiatric Association, 1980.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd edition - Revised. Washington D.C.: American Psychiatric Association, 1987.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, D.C.: American Psychiatric Association, 1994.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM-IV-TR). Washington, D.C.: American Psychiatric Association, 2000.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington (VA): American Psychiatric Association, 2013.
13. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007954]
14. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475(7354):91-5.
15. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. Journal of Clinical Psychiatry 2006;67(9):1428-34.
16. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment 2001;5(33):1-56.
17. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004;57(3):229-36.
18. Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Frontiers in Pharmacology 2013;4:161.
19. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Therapeutic Advances in Psychopharmacology 2014;4(2):75-99.
20. Canadian Agency for Drugs and Technologies in Health. Intravenous Ketamine for the Treatment of Mental Health Disorders: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON) 2014 Aug:http://www.cadth.ca/en/products/rapid-response/publication/4759.
21. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58.
22. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. British Medical Journal 2013;346:f3646.
23. Dutta A, McKie S, Deakin JF. Ketamine and other potential glutamate antidepressants. Psychiatry Research 2015; Vol. 225, issue 1-2:1-13. [DOI: 10.1016/j.psychres.2014.10.028]
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629-34.
25. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving crossover trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
26. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26(1):57-63.
27. Furukawa TA, Guyatt GH, Griffith LE. An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72-6.
28. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
29. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
30. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007;297(5):468-70.
31. Furukawa TA, Akechi T, Azuma H, Okuyama T, Higuchi T. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology 2007;27(5):531-4.
32. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381(9878):1672-82.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): U.S. Department of Health and Human Services, 1976.
34. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. British Medical Journal 1998;316(7132):690-3.
35. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
37. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
39. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
41. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 2007;27(43):11496-500.
42. Howland RH. Induction of mania with serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 1996;16(6):425-7.
43. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002;59(6):530-7.
44. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry 2003;60(3):261-9.
45. Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. American Journal of Psychiatry 2012;169(11):1150-6.
46. Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Guideline Development Group. Assessment and management of bipolar disorder: summary of updated NICE guidance. British Medical Journal 2014;349:g5673.
47. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion on Therapeutic Targets 2005;9(1):153-68.
48. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012;26(3):189-204.
49. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 2015; Vol. 45, issue 4:693-704.
50. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry 2011;68(3):241-51.
51. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
52. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). Journal of Affective Disorders 2003;77(3):255-60.
53. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384(9947):1005-70.
54. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 2014;156:24-35.
55. Rasmussen KG. Psychiatric side effects of ketamine in hospitalized medical patients administered subanesthetic doses for pain control. Acta Neuropsychiatrica 2014;26(4):230-3.
56. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia 1989;36(2):186-97.
57. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
58. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 1978;35(6):773-82.
59. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53(11):1119-29.
60. Suh T, Gallo JJ. Symptom profiles of depression among general medical service users compared with specialty mental health service users. Psychological Medicine 1997;27(5):1051-63.
61. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). European Neuropsychopharmacology 1997;7(1):9-24.
62. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
63. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12. Physical and Mental Health Summary Scales. Lincoln (RI): QualityMetric Inc., 1998.
64. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
65. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569-85.
66. Wing JK, Beevor AS, Curtis RH, Park SBG, Burns A. Health of the nation outcome scales (HoNOS). Research and development. British Journal of Psychiatry 1998;172:11-8.
67. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006;63(8):856-64.